Effectiveness of referral system for the management of heart failure with tolvapta
Not Applicable
- Conditions
- congestive heart failure
- Registration Number
- JPRN-UMIN000019675
- Lead Sponsor
- Cardiovascular Center, Anjo Kosei Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Petients with history of the adverse effects of tolvaptan 2. Patients on dialysis 3. Pregnant women, women who may be pregnant, and breast-feeding women 4. Patients with serum sodium over 145 mEq/L 5. Patients who cannot take medicine orally
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Scale of signs, symptoms, and parameters of congestion at 6 months after the administration of tolvaptan
- Secondary Outcome Measures
Name Time Method all-cause mortality, cardiovascular mortality, re-admission for heart failure, and chenges in kidney function